Pyxis Oncology, Inc. PYXS
1.58 USD 0.00 (+0.00%)
Regular-session close
1.66 +0.08 +5.06%
Pre-market · Nov 16, 7:22 AM ET
1.52 Day range 1.60
1.03 52-week range 5.55
- YTD
- +37.39%
- 1 year
- -64.73%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 10.00 +532.9% upside
Now 1.58
- Target (low)
- 5.00
- Target (mean)
- 10.00
- Target (high)
- 13.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy2
- Buy5
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 8
- 2 months ago 7
- 3 months ago 7
Revenue and earnings: history and forecast
What PYXS reported, and what analysts expect for the next two fiscal years
Earnings per share
Analysts expect earnings per share of -1.00 in the current fiscal year.
Fiscal years. Estimates are the analyst consensus and change as analysts revise them; the percentages are the change on the year before. Earnings per share is on the basis analysts estimate, which can differ from the reported (GAAP) figure.
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.28571 | -0.37 – -0.23 | -0.33 | +13.4% | 0 | 0.0% | 7 |
| Next quarter | -0.33 | -0.38 – -0.29 | -0.06 | -450.0% | 0 | -100.0% | 3 |
| Current year | -1.00 | -1.29 – -0.88 | -1.85 | +45.8% | 13.80M | 0.0% | 7 |
| Next year | -1.19 | -1.35 – -0.98 | -1.00 | -18.8% | 0 | -100.0% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 20, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Nov 21, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 21, 2024 | William Blair | Downgrade | Outperform | Market Perform |
| Nov 21, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 8, 2024 | Stephens & Co. | Initiated | — | Overweight |
| Sep 19, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Aug 16, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 8, 2024 | Stifel | Initiated | — | Buy |
| May 16, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 10, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 22, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Mar 22, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 9, 2024 | BTIG | Initiated | — | Buy |
| Jan 23, 2024 | Leerink Partners | Initiated | — | Outperform |
| Nov 30, 2023 | HC Wainwright & Co. | Initiated | — | Buy |
| Sep 5, 2023 | RBC Capital | Initiated | — | Outperform |
| Jul 31, 2023 | EF Hutton | Initiated | — | Buy |
| Mar 23, 2023 | Credit Suisse | Reiterated | — | Outperform |
| Nov 2, 2021 | B of A Securities | Initiated | — | Neutral |
| Nov 2, 2021 | Jefferies | Initiated | — | Buy |
| Nov 2, 2021 | Credit Suisse | Initiated | — | Outperform |
Included in Plus and up
Sign in to see Analyst trend
Two years of the analyst rating mix and the average price target against the price.
